Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) — Net Asset Quality Index
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) has a Net Asset Quality Index of 65.8% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥3.80 Billion minus total liabilities of CN¥1.30 Billion yields net assets of CN¥2.50 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check 301096 financial resilience to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Net Asset Quality Index Over Time (2019–2025)
This chart shows how Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s Net Asset Quality Index has evolved across 7 annual periods from 2019 to 2025. As of March 2026, the index stands at 65.8%, representing net assets of CN¥2.50 Billion against total assets of CN¥3.80 Billion CNY. See how liquid is Hangzhou Bio-Sincerity Pharma-Tech Co.Lt's working capital to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (2019–2025)
The table below presents the year-by-year Net Asset Quality Index for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. from 2019 to 2025, covering 7 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Hangzhou Bio-Sincerity Pharma-Tech Co.Lt stock valuation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 67.5% | CN¥2.49 Billion | CN¥3.69 Billion | CN¥1.20 Billion | ▼ -1.8 pp |
| 2024 | 69.3% | CN¥2.58 Billion | CN¥3.72 Billion | CN¥1.14 Billion | ▼ -3.8 pp |
| 2023 | 73.2% | CN¥2.68 Billion | CN¥3.67 Billion | CN¥984.97 Million | ▼ -11.6 pp |
| 2022 | 84.7% | CN¥2.48 Billion | CN¥2.93 Billion | CN¥447.45 Million | ▲ +5.5 pp |
| 2021 | 79.2% | CN¥2.32 Billion | CN¥2.92 Billion | CN¥607.10 Million | ▲ +27.7 pp |
| 2020 | 51.5% | CN¥339.54 Million | CN¥658.75 Million | CN¥319.20 Million | ▼ -22.1 pp |
| 2019 | 73.6% | CN¥278.74 Million | CN¥378.63 Million | CN¥99.89 Million | — |